AI Summary
In a phase 3 trial, two different doses of crisugabalin showed significant pain reduction in adults with postherpetic neuralgia compared to a placebo.
Two different doses of crisugabalin resulted in significantly greater pain reductions in adults with postherpetic neuralgia than placebo in a phase 3 trial.
Medscape Medical News